Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

F. Frassoni, M. Labopin, E. Gluckman, H. G. Prentice, J. P. Vernant, F. Zwaan, A. Granena, G. Gahrton, T. De Witte, A. Gratwohl, J. Reiffers, N. C. Gorin

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

To evaluate whether the results of bone marrow transplantation have improved in Europe with time, we analyzed the outcome for 2195 patients with acute leukemia. 1405 had acute myeloid leukemia (AML) and 790 had acute lymphoblastic leukemia (ALL), and were allografted in first complete remission between September 1979 and December 1991 with marrow from an HLA-identical sibling donor. We found a continuing improvement more evident since 1987 for AML and since 1986 for ALL. A substantial reduction in the 3 years transplant related mortality (TRM): 26 vs 39% for AML (P=10-4), and 25 vs 39% for ALL (P=10-4), has resulted in an increase of the 5-year actuarial leukemia-free survival (LFS). 57 vs 45% for AML (P <10-4) and 54 vs 45% (P= 10-4) for ALL. Four important changes have occurred. (1) Graft-versus-host disease (GVHD) prevention has involved an increased use of cyclosporin A (CsA) alone and subsequently its use in combination with methotrexate: this was associated with lower TRM both in AML and ALL; (2) Use of total body irradiation as pretransplant regimen has decreased; (3) a shorter interval from remission to BMT is more common; (4) an older population of patients has undergone BMT. Multivariate analyses were performed separately in AML and ALL. In AML four variables significantly influenced TRM favorably: year of BMT (P = 10-4), younger age at BMT (P = 10-4), prevention of GVHD including CsA (P = 0.008), sex match other than female donor to male recipient (P = 0.002). The relapse incidence (RI) was lower in patients with FAB M1-2-3 vs M4-5 (P = 0.0004). The LFS improved by year of BMT (P = 0.0004), younger age at BMT (P = 10-4), prevention of GVHD including CsA (P = 0.01), FAB Ml-2-3 (P = 0.03). In ALL, three variables were associated with a lower TRM: year of BMT (P=10-4), younger age at BMT (P = 10-4), sex combination other than female to male (P = 0.008). The LFS was better after 1986 (P = 0.0004) and in younger patients (P = 10-4). However a better outcome after 1986/87 was observed in patients receiving the same GVHD prophylaxis: therefore, other unidentified factors resulting in better patient care have also contributed to this. The improved results of allogeneic BMT are entirely related to a reduction in TRM without loss of the antileukemic effect since relapse incidence has not changed over the years.

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalBone Marrow Transplantation
Volume17
Issue number1
Publication statusPublished - Jan 1996

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Leukemia
Graft vs Host Disease
Transplants
Mortality
Cyclosporine
Survival
Tissue Donors
Recurrence
Whole-Body Irradiation
Incidence
Methotrexate
Siblings
Patient Care
Multivariate Analysis
Bone Marrow
Population

Keywords

  • Acute leukemia
  • Allogeneic BMT
  • EBMT
  • Improvement

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). / Frassoni, F.; Labopin, M.; Gluckman, E.; Prentice, H. G.; Vernant, J. P.; Zwaan, F.; Granena, A.; Gahrton, G.; De Witte, T.; Gratwohl, A.; Reiffers, J.; Gorin, N. C.

In: Bone Marrow Transplantation, Vol. 17, No. 1, 01.1996, p. 13-18.

Research output: Contribution to journalArticle

Frassoni, F, Labopin, M, Gluckman, E, Prentice, HG, Vernant, JP, Zwaan, F, Granena, A, Gahrton, G, De Witte, T, Gratwohl, A, Reiffers, J & Gorin, NC 1996, 'Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)', Bone Marrow Transplantation, vol. 17, no. 1, pp. 13-18.
Frassoni, F. ; Labopin, M. ; Gluckman, E. ; Prentice, H. G. ; Vernant, J. P. ; Zwaan, F. ; Granena, A. ; Gahrton, G. ; De Witte, T. ; Gratwohl, A. ; Reiffers, J. ; Gorin, N. C. / Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). In: Bone Marrow Transplantation. 1996 ; Vol. 17, No. 1. pp. 13-18.
@article{1efa8c623e854ae7b44c55ed4679b82c,
title = "Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)",
abstract = "To evaluate whether the results of bone marrow transplantation have improved in Europe with time, we analyzed the outcome for 2195 patients with acute leukemia. 1405 had acute myeloid leukemia (AML) and 790 had acute lymphoblastic leukemia (ALL), and were allografted in first complete remission between September 1979 and December 1991 with marrow from an HLA-identical sibling donor. We found a continuing improvement more evident since 1987 for AML and since 1986 for ALL. A substantial reduction in the 3 years transplant related mortality (TRM): 26 vs 39{\%} for AML (P=10-4), and 25 vs 39{\%} for ALL (P=10-4), has resulted in an increase of the 5-year actuarial leukemia-free survival (LFS). 57 vs 45{\%} for AML (P <10-4) and 54 vs 45{\%} (P= 10-4) for ALL. Four important changes have occurred. (1) Graft-versus-host disease (GVHD) prevention has involved an increased use of cyclosporin A (CsA) alone and subsequently its use in combination with methotrexate: this was associated with lower TRM both in AML and ALL; (2) Use of total body irradiation as pretransplant regimen has decreased; (3) a shorter interval from remission to BMT is more common; (4) an older population of patients has undergone BMT. Multivariate analyses were performed separately in AML and ALL. In AML four variables significantly influenced TRM favorably: year of BMT (P = 10-4), younger age at BMT (P = 10-4), prevention of GVHD including CsA (P = 0.008), sex match other than female donor to male recipient (P = 0.002). The relapse incidence (RI) was lower in patients with FAB M1-2-3 vs M4-5 (P = 0.0004). The LFS improved by year of BMT (P = 0.0004), younger age at BMT (P = 10-4), prevention of GVHD including CsA (P = 0.01), FAB Ml-2-3 (P = 0.03). In ALL, three variables were associated with a lower TRM: year of BMT (P=10-4), younger age at BMT (P = 10-4), sex combination other than female to male (P = 0.008). The LFS was better after 1986 (P = 0.0004) and in younger patients (P = 10-4). However a better outcome after 1986/87 was observed in patients receiving the same GVHD prophylaxis: therefore, other unidentified factors resulting in better patient care have also contributed to this. The improved results of allogeneic BMT are entirely related to a reduction in TRM without loss of the antileukemic effect since relapse incidence has not changed over the years.",
keywords = "Acute leukemia, Allogeneic BMT, EBMT, Improvement",
author = "F. Frassoni and M. Labopin and E. Gluckman and Prentice, {H. G.} and Vernant, {J. P.} and F. Zwaan and A. Granena and G. Gahrton and {De Witte}, T. and A. Gratwohl and J. Reiffers and Gorin, {N. C.}",
year = "1996",
month = "1",
language = "English",
volume = "17",
pages = "13--18",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

AU - Frassoni, F.

AU - Labopin, M.

AU - Gluckman, E.

AU - Prentice, H. G.

AU - Vernant, J. P.

AU - Zwaan, F.

AU - Granena, A.

AU - Gahrton, G.

AU - De Witte, T.

AU - Gratwohl, A.

AU - Reiffers, J.

AU - Gorin, N. C.

PY - 1996/1

Y1 - 1996/1

N2 - To evaluate whether the results of bone marrow transplantation have improved in Europe with time, we analyzed the outcome for 2195 patients with acute leukemia. 1405 had acute myeloid leukemia (AML) and 790 had acute lymphoblastic leukemia (ALL), and were allografted in first complete remission between September 1979 and December 1991 with marrow from an HLA-identical sibling donor. We found a continuing improvement more evident since 1987 for AML and since 1986 for ALL. A substantial reduction in the 3 years transplant related mortality (TRM): 26 vs 39% for AML (P=10-4), and 25 vs 39% for ALL (P=10-4), has resulted in an increase of the 5-year actuarial leukemia-free survival (LFS). 57 vs 45% for AML (P <10-4) and 54 vs 45% (P= 10-4) for ALL. Four important changes have occurred. (1) Graft-versus-host disease (GVHD) prevention has involved an increased use of cyclosporin A (CsA) alone and subsequently its use in combination with methotrexate: this was associated with lower TRM both in AML and ALL; (2) Use of total body irradiation as pretransplant regimen has decreased; (3) a shorter interval from remission to BMT is more common; (4) an older population of patients has undergone BMT. Multivariate analyses were performed separately in AML and ALL. In AML four variables significantly influenced TRM favorably: year of BMT (P = 10-4), younger age at BMT (P = 10-4), prevention of GVHD including CsA (P = 0.008), sex match other than female donor to male recipient (P = 0.002). The relapse incidence (RI) was lower in patients with FAB M1-2-3 vs M4-5 (P = 0.0004). The LFS improved by year of BMT (P = 0.0004), younger age at BMT (P = 10-4), prevention of GVHD including CsA (P = 0.01), FAB Ml-2-3 (P = 0.03). In ALL, three variables were associated with a lower TRM: year of BMT (P=10-4), younger age at BMT (P = 10-4), sex combination other than female to male (P = 0.008). The LFS was better after 1986 (P = 0.0004) and in younger patients (P = 10-4). However a better outcome after 1986/87 was observed in patients receiving the same GVHD prophylaxis: therefore, other unidentified factors resulting in better patient care have also contributed to this. The improved results of allogeneic BMT are entirely related to a reduction in TRM without loss of the antileukemic effect since relapse incidence has not changed over the years.

AB - To evaluate whether the results of bone marrow transplantation have improved in Europe with time, we analyzed the outcome for 2195 patients with acute leukemia. 1405 had acute myeloid leukemia (AML) and 790 had acute lymphoblastic leukemia (ALL), and were allografted in first complete remission between September 1979 and December 1991 with marrow from an HLA-identical sibling donor. We found a continuing improvement more evident since 1987 for AML and since 1986 for ALL. A substantial reduction in the 3 years transplant related mortality (TRM): 26 vs 39% for AML (P=10-4), and 25 vs 39% for ALL (P=10-4), has resulted in an increase of the 5-year actuarial leukemia-free survival (LFS). 57 vs 45% for AML (P <10-4) and 54 vs 45% (P= 10-4) for ALL. Four important changes have occurred. (1) Graft-versus-host disease (GVHD) prevention has involved an increased use of cyclosporin A (CsA) alone and subsequently its use in combination with methotrexate: this was associated with lower TRM both in AML and ALL; (2) Use of total body irradiation as pretransplant regimen has decreased; (3) a shorter interval from remission to BMT is more common; (4) an older population of patients has undergone BMT. Multivariate analyses were performed separately in AML and ALL. In AML four variables significantly influenced TRM favorably: year of BMT (P = 10-4), younger age at BMT (P = 10-4), prevention of GVHD including CsA (P = 0.008), sex match other than female donor to male recipient (P = 0.002). The relapse incidence (RI) was lower in patients with FAB M1-2-3 vs M4-5 (P = 0.0004). The LFS improved by year of BMT (P = 0.0004), younger age at BMT (P = 10-4), prevention of GVHD including CsA (P = 0.01), FAB Ml-2-3 (P = 0.03). In ALL, three variables were associated with a lower TRM: year of BMT (P=10-4), younger age at BMT (P = 10-4), sex combination other than female to male (P = 0.008). The LFS was better after 1986 (P = 0.0004) and in younger patients (P = 10-4). However a better outcome after 1986/87 was observed in patients receiving the same GVHD prophylaxis: therefore, other unidentified factors resulting in better patient care have also contributed to this. The improved results of allogeneic BMT are entirely related to a reduction in TRM without loss of the antileukemic effect since relapse incidence has not changed over the years.

KW - Acute leukemia

KW - Allogeneic BMT

KW - EBMT

KW - Improvement

UR - http://www.scopus.com/inward/record.url?scp=0030061801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030061801&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 13

EP - 18

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -